IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i7p4260-d785937.html
   My bibliography  Save this article

Predicting Response to Anthracyclines in Ovarian Cancer

Author

Listed:
  • Annamaria Ferrero

    (Academic Department of Gynaecology and Obstetrics, Mauriziano Hospital, 10128 Torino, Italy)

  • Martina Borghese

    (Department of Gynecology and Obstetrics, Santa Croce and Carle Hospital, 12100 Cuneo, Italy)

  • Stefano Restaino

    (Obstetrics and Gynecology Unit, Department of Obstetrics, Gynecology and Pediatrics, Department of Medical Area DAME, Udine University Hospital, 33100 Udine, Italy)

  • Andrea Puppo

    (Department of Gynecology and Obstetrics, Santa Croce and Carle Hospital, 12100 Cuneo, Italy)

  • Giuseppe Vizzielli

    (Clinic of Obstetrics and Gynaecology, Department of Medical Area (DAME), University of Udine, “Santa Maria della Misericordia” Hospital, Azienda Sanitaria Ospedaliera Friuli Centrale, 33100 Udine, Italy)

  • Nicoletta Biglia

    (Academic Department of Gynaecology and Obstetrics, Mauriziano Hospital, 10128 Torino, Italy)

Abstract

(1) Background: Anthracyclines are intriguing drugs, representing one of the cornerstones of both first and subsequent-lines of chemotherapy in ovarian cancer (OC). Their efficacy and mechanisms of action are related to the hot topics of OC clinical research, such as BRCA status and immunotherapy. Prediction of response to anthracyclines is challenging and no markers can predict certain therapeutic success. The current narrative review provides a summary of the clinical and biological mechanisms involved in the response to anthracyclines. (2) Methods: A MEDLINE search of the literature was performed, focusing on papers published in the last two decades. (3) Results and Conclusions: BRCA mutated tumors seem to show a higher response to anthracyclines compared to sporadic tumors and the severity of hand–foot syndrome and mucositis may be a predictive marker of PLD efficacy. CA125 can be a misleading marker of clinical response during treatment with anthracyclines, the response of which also appears to depend on OC histology. Immunochemistry, in particular HER-2 expression, could be of some help in predicting the response to such drugs, and high levels of mutated p53 appear after exposure to anthracyclines and impair their antitumor effect. Finally, organoids from OC are promising for drug testing and prediction of response to chemotherapy.

Suggested Citation

  • Annamaria Ferrero & Martina Borghese & Stefano Restaino & Andrea Puppo & Giuseppe Vizzielli & Nicoletta Biglia, 2022. "Predicting Response to Anthracyclines in Ovarian Cancer," IJERPH, MDPI, vol. 19(7), pages 1-15, April.
  • Handle: RePEc:gam:jijerp:v:19:y:2022:i:7:p:4260-:d:785937
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/7/4260/pdf
    Download Restriction: no

    File URL: https://www.mdpi.com/1660-4601/19/7/4260/
    Download Restriction: no
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:7:p:4260-:d:785937. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.